KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases

被引:42
|
作者
Lahti, Steven J. [1 ]
Xing, Minzhi [1 ]
Zhang, Di [3 ]
Lee, James J. [2 ,4 ]
Magnetta, Michael J. [1 ]
Kim, Hyun S. [1 ,4 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Radiol, Div Intervent Radiol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA
[4] Univ Pittsburgh, Inst Canc, Canc Therapeut Program, Pittsburgh, PA USA
关键词
KIRSTEN RAS MUTATIONS; HUMAN TUMOR-CELLS; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; PHASE-III; CETUXIMAB; FLUOROURACIL; LEUCOVORIN; RADIORESISTANCE; MICROSPHERES;
D O I
10.1016/j.jvir.2015.05.032
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status as a prognostic factor for survival after yttrium-90 (Y-90) radioembolization for colorectal cancer (CRC) liver metastases. Materials and Methods: Consecutive patients with unresectable CRC liver metastases and documented KRAS mutation status who were treated with Y-90 radioembolization during the period 2007-2014 were investigated. Patient demographics, disease characteristics, therapy regimens, and overall survival (OS) from first Y-90 radioembolization were compared between patients with KRAS wild-type (wt) and mutant status. Kaplan-Meier estimation and Cox regression were used for survival analysis and to assess independent prognostic factors for OS. Results: Of 186 patients, 104 underwent KRAS mutation analysis before Y-90 radioembolization, with 45 (43.3%) identified as mutant. The wt and mutant groups were similar in demographics, liver status, overall performance status, and tumor characteristics (all P > .05). Mean time from liver metastasis to Y-90 radioembolization was greater in patients with KRAS wt status (P = .033). A greater percentage of wt patients received anti-epidermal growth factor receptor therapies before Y-90 radioembolization (66.1% vs 8.9%; P < .001). Median OS from first Y-90 radioembolization was significantly greater in KRAS wt patients (9.5 mo vs 4.8 mo; P = .041). Univariate analysis identified Child-Pugh class, carcinoembryonic antigen (CEA), chemotherapy after Y-90 radioembolization, KRAS status, and treatment-induced toxicity as prognostic factors for OS. Multivariate Cox regression analysis demonstrated Child-Pugh class, CEA, and KRAS status to be independent prognostic factors for OS, even when correcting for the effect of chemotherapy after Y-90 radioembolization. Conclusions: Patients with CRC and KRAS wt may derive greater survival benefit from Y-90 radioembolization therapy than patients with KRAS mutant.
引用
收藏
页码:1102 / 1111
页数:10
相关论文
共 50 条
  • [31] Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review
    Alonso, J. C.
    Casans, I
    Gonzalez, F. M.
    Fuster, D.
    Rodriguez, A.
    Sanchez, N.
    Oyaguez, I
    Williams, A. O.
    Espinoza, N.
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [32] Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review
    JC Alonso
    I Casans
    FM González
    D Fuster
    A Rodríguez
    N Sánchez
    I Oyagüez
    AO Williams
    N Espinoza
    BMC Gastroenterology, 23
  • [33] MR Imaging Volumetric Response after Yttrium-90 Radioembolization for Colorectal Liver Metastases: Predictability at Baseline and Correlation with Survival
    Ludemann, Willie-Magnus
    Wieners, Gero
    Franz, Klaus
    Hardt, Juliane
    Pustelnik, Daniel
    Boening, Georg
    Amthauer, Holger
    Gebauer, Bernhard
    Kahn, Johannes
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2023, 34 (02) : 244 - 252.e1
  • [34] Yttrium-90 Transarterial Radioembolization of Primary Lung Cancer Metastases to the Liver
    Alexander, Erica S.
    Petre, Elena N.
    Zhao, Ken
    Sotirchos, Vlasios
    Namakydoust, Azadeh
    Moussa, Amgad
    Yuan, Gavin
    Sofocleous, Constantinos T.
    Solomon, Stephen B.
    Ziv, Etay
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 35 (02) : 214 - 225.e2
  • [35] Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
    Flamen, Patrick
    Vanderlinden, Bruno
    Delatte, Philippe
    Ghanem, Ghanem
    Ameye, Lieveke
    Van Den Eynde, Marc
    Hendlisz, Alain
    PHYSICS IN MEDICINE AND BIOLOGY, 2008, 53 (22): : 6591 - 6603
  • [36] Yttrium-90 (Y-90) Radioembolization for Colorectal Cancer (CRC) Liver Metastases: A Single Institution Experience
    Nace, G. W.
    Steel, J. L.
    Gamblin, T. C.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 : 89 - 90
  • [37] Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases A Critical Appraisal of 48 Cases
    Saxena, Akshat
    Chua, Terence C.
    Bester, Lourens
    Kokandi, Adel
    Morris, David L.
    ANNALS OF SURGERY, 2010, 251 (05) : 910 - 916
  • [38] Factors Predicting Response and Survival after Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases: A Critical Appraisal of 48 Cases
    Saxena, A.
    Morris, D. L.
    Chua, T. C.
    Bester, L.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S76 - S76
  • [39] Radioembolization of Colorectal Hepatic Metastases Using Yttrium-90 Microspheres
    Mulcahy, Mary F.
    Lewandowski, Robert J.
    Ibrahim, Saad M.
    Sato, Kent T.
    Ryu, Robert K.
    Atassi, Bassel
    Newman, Steven
    Talamonti, Mark
    Omary, Reed A.
    Benson, Al, III
    Salem, Riad
    CANCER, 2009, 115 (09) : 1849 - 1858
  • [40] Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience
    Pieper, Claus Christian
    Meyer, Carsten
    Wilhelm, Kai E.
    Block, Wolfgang
    Nadal, Jennifer
    Ahmadzadehfar, Hojjat
    Willinek, Winfried Albert
    Schild, Hans Heinz
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 27 (09) : 1305 - 1315